ustekinumab   Click here for help

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
Approved drug Immunopharmacology Ligand
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
ustekinumab-auub; ABP 654WezlanaAmgenApproved (2023 FDA)As per reference agent; Interchangeable with reference agent
ustekinumab-aekn; AVT04SelarsdiAlvotech/Teva PharmaceuticalsApproved (2024 FDA)As per reference agent
Bioactivity Comments
The patent covering the production and use of ustekinumab (US6902734 [1]) does not provide affinity values for specific antibody clones, therefore we have included the stated range of affinities determined in the production and testing process in the interaction table below..
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-12B Primary target of this compound Hs Antibody Inhibition >9.0 – 11.1 pKd - 1
⤷ pKd >9.0 – 11.1 (Kd <1x10-9 – 7x10-12 M) [1]